Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure that may offer an alternative to traditional microfracture and complex cell-based therapies. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists.
Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC® has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled, positioning Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.
The Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue including inflamed cartilage and bone. GelrinC® is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process. This off-the-shelf solution could address a significant unmet need, as current treatments like microfracture often yield fibrocartilage with inferior durability, while cell-based therapies are costly and require two surgeries.
Regentis is focusing on commercial milestones, including expanding European market access following CE Mark approval and completing the U.S. pivotal study. If successful, GelrinC® could become the first approved off-the-shelf regenerative therapy for knee cartilage repair in the U.S., offering a simpler, less invasive option for patients. For a full corporate profile, visit https://ibn.fm/bpPp6.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the Company's SEC filings. See full terms at http://IBN.fm/Disclaimer.